Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is ...
Hosted on MSN1mon
GSK's belantamab mafodotin reduced death risk by 42% in studyGSK (NYSE:GSK) reported that a study showed its ... China, United Kingdom, Canada and Switzerland.
GSK has agreed to acquire Canada’s Bellus Health for around $2 billion, bolting on a late-stage drug candidate for chronic refractory cough. The $14.75-per-share deal will add P2X3 antagonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback